$HRGN
Harvard Apparatus Regenerative Technology Inc

2016 Q2 Form 10-Q Financial Statement

#000114420416101014 Filed on May 12, 2016

View on sec.gov

Income Statement

Concept 2016 Q2 2016 Q1 2015 Q1
Revenue $28.00K $0.00 $0.00
YoY Change -61.64% -100.0%
Cost Of Revenue $44.00K $0.00 $0.00
YoY Change 18.92% -100.0%
Gross Profit -$16.00K $0.00 $0.00
YoY Change -144.44% -100.0%
Gross Profit Margin -57.14%
Selling, General & Admin $1.230M $1.094M $1.378M
YoY Change -64.68% -20.61% -23.44%
% of Gross Profit
Research & Development $1.680M $1.378M $1.242M
YoY Change 60.0% 10.95% 2.05%
% of Gross Profit
Depreciation & Amortization $110.0K $111.0K $112.0K
YoY Change -8.33% -0.89% 100.0%
% of Gross Profit
Operating Expenses $2.906M $2.472M $2.620M
YoY Change -35.92% -5.65% -13.16%
Operating Profit -$2.922M -$2.472M -$2.620M
YoY Change -35.05% -5.65% -12.84%
Interest Expense $210.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 -$3.000K
YoY Change -100.0%
Pretax Income -$2.712M -$2.472M -$2.623M
YoY Change -39.72% -5.76% -12.74%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.712M -$2.472M -$2.623M
YoY Change -39.72% -5.76% -12.74%
Net Earnings / Revenue -9685.71%
Basic Earnings Per Share
Diluted Earnings Per Share -$3.474M -$3.479M -$5.955M
COMMON SHARES
Basic Shares Outstanding 14.11M shares 14.11M shares 10.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q2 2016 Q1 2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.100M $4.850M $12.16M
YoY Change -20.04% -60.12% -3.57%
Cash & Equivalents $8.100M $4.848M $12.16M
Short-Term Investments
Other Short-Term Assets $160.0K $490.0K $270.0K
YoY Change -5.88% 81.48% -22.86%
Inventory $50.00K $79.00K $210.0K
Prepaid Expenses $485.0K $269.0K
Receivables $40.00K $18.00K $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.340M $5.430M $12.65M
YoY Change -21.17% -57.07% -3.44%
LONG-TERM ASSETS
Property, Plant & Equipment $1.080M $1.135M $1.269M
YoY Change -10.0% -10.56% 66.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.080M $1.135M $1.269M
YoY Change -10.0% -10.56% 66.97%
TOTAL ASSETS
Total Short-Term Assets $8.340M $5.430M $12.65M
Total Long-Term Assets $1.080M $1.135M $1.269M
Total Assets $9.420M $6.565M $13.92M
YoY Change -20.03% -52.83% 0.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $264.0K $261.0K
YoY Change 87.5% 1.15% -36.34%
Accrued Expenses $410.0K $120.0K $400.0K
YoY Change 86.36% -70.0% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.940M $388.0K $674.0K
YoY Change 228.81% -42.43% -22.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.940M $388.0K $674.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.940M $388.0K $674.0K
YoY Change 228.81% -42.43% -22.53%
SHAREHOLDERS EQUITY
Retained Earnings -$27.21M -$15.66M
YoY Change 73.78% 214.42%
Common Stock $141.0K $101.0K
YoY Change 39.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.480M $6.177M $13.24M
YoY Change
Total Liabilities & Shareholders Equity $9.420M $6.565M $13.92M
YoY Change -20.04% -52.84% 0.43%

Cashflow Statement

Concept 2016 Q2 2016 Q1 2015 Q1
OPERATING ACTIVITIES
Net Income -$2.712M -$2.472M -$2.623M
YoY Change -39.72% -5.76% -12.74%
Depreciation, Depletion And Amortization $110.0K $111.0K $112.0K
YoY Change -8.33% -0.89% 100.0%
Cash From Operating Activities -$1.500M -$2.480M -$1.690M
YoY Change -25.74% 46.75% 19.86%
INVESTING ACTIVITIES
Capital Expenditures -$90.00K $128.0K $6.000K
YoY Change 800.0% 2033.33% -97.52%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$90.00K -$130.0K -$10.00K
YoY Change 800.0% 1200.0% -95.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $3.237M
YoY Change -100.0% 1210.53%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.850M 0.000 8.590M
YoY Change -100.0% 3336.0%
NET CHANGE
Cash From Operating Activities -1.500M -2.480M -1.690M
Cash From Investing Activities -90.00K -130.0K -10.00K
Cash From Financing Activities 4.850M 0.000 8.590M
Net Change In Cash 3.260M -2.610M 6.890M
YoY Change -260.59% -137.88% -592.14%
FREE CASH FLOW
Cash From Operating Activities -$1.500M -$2.480M -$1.690M
Capital Expenditures -$90.00K $128.0K $6.000K
Free Cash Flow -$1.410M -$2.608M -$1.696M
YoY Change -29.85% 53.77% 2.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q1 us-gaap Assets Current
AssetsCurrent
5430000 USD
CY2016Q1 us-gaap Inventory Net
InventoryNet
79000 USD
CY2016Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
485000 USD
CY2016Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
124000 USD
CY2015Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
297000 USD
CY2016Q1 us-gaap Liabilities Current
LiabilitiesCurrent
388000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
654000 USD
CY2016Q1 us-gaap Liabilities
Liabilities
388000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
654000 USD
CY2016Q1 us-gaap Common Stock Value
CommonStockValue
141000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
141000 USD
CY2016Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27211000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-24739000 USD
CY2016Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33255000 USD
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32908000 USD
CY2016Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000 USD
CY2016Q1 us-gaap Stockholders Equity
StockholdersEquity
6177000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
8302000 USD
CY2016Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q1 dei Document Type
DocumentType
10-Q
CY2016Q1 dei Amendment Flag
AmendmentFlag
false
CY2016Q1 us-gaap Cash
Cash
4848000 USD
CY2016Q1 dei Document Period End Date
DocumentPeriodEndDate
2016-03-31
CY2016Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q4 us-gaap Cash
Cash
7456000 USD
CY2016Q1 dei Entity Registrant Name
EntityRegistrantName
Biostage, Inc.
CY2016Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001563665
CY2016Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q1 dei Trading Symbol
TradingSymbol
BSTG
CY2016Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14110540 shares
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
738000 USD
CY2015Q1 us-gaap Depreciation
Depreciation
112000 USD
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1378000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1242000 USD
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
2472000 USD
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
2620000 USD
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2472000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2620000 USD
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-2472000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2623000 USD
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14108000 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8873000 shares
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2015Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000 USD
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2472000 USD
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2632000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8594000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7456000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5272000 USD
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4000 USD
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-137000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-109000 USD
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-173000 USD
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
126000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2480000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1687000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
128000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-128000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6000 USD
CY2016Q1 us-gaap Assets
Assets
6565000 USD
CY2015Q4 us-gaap Assets
Assets
8956000 USD
CY2016Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
264000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
357000 USD
CY2015Q4 us-gaap Inventory Net
InventoryNet
75000 USD
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
330000 USD
CY2015Q4 us-gaap Assets Current
AssetsCurrent
7882000 USD
CY2016Q1 us-gaap Revenues
Revenues
0 USD
CY2015Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 USD
CY2016Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6565000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8956000 USD
CY2016Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
18000 USD
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21000 USD
CY2016Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1135000 USD
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1074000 USD
CY2015Q1 us-gaap Revenues
Revenues
0 USD
CY2016Q1 us-gaap Cost Of Revenue
CostOfRevenue
0 USD
CY2016Q1 us-gaap Gross Profit
GrossProfit
0 USD
CY2015Q1 us-gaap Gross Profit
GrossProfit
0 USD
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2472000 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2623000 USD
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
347000 USD
CY2016Q1 us-gaap Depreciation
Depreciation
111000 USD
CY2016Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
0 USD
CY2015Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-21000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3237000 USD
CY2016Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
0 USD
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-9000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2608000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6892000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4848000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12164000 USD
CY2016Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
5357000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155000 USD
CY2015Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-48000 USD
CY2015Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1100000 USD
CY2015Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
9700000 USD
CY2015Q1 bstg Proceeds From Issuance Of Stock To Underwriters
ProceedsFromIssuanceOfStockToUnderwriters
8600000 USD
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3253118 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
690000 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
208188 shares
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
3734930 shares
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.29
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.66
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
3.74
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.97
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2016Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000 shares
CY2016Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 USD
CY2015Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-5000 USD
CY2016Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1094000 USD
CY2015Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1378000 USD
CY2016Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
44000 USD
CY2015Q1 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
CY2016Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q1 bstg Product Distribution Agreement Term
ProductDistributionAgreementTerm
P10Y
CY2016Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">Reclassification</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><i><font style="FONT-SIZE: 10pt">&#160;</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Sales and marketing expenses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">107</font> thousand for the three months ended March 31, 2015 has been reclassified to selling, general and administrative expenses to conform to the 2016 presentation.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14101395 shares
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14110540 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14101395 shares
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14110540 shares
CY2016Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.09

Files In Submission

Name View Source Status
0001144204-16-101014-index-headers.html Edgar Link pending
0001144204-16-101014-index.html Edgar Link pending
0001144204-16-101014.txt Edgar Link pending
0001144204-16-101014-xbrl.zip Edgar Link pending
bstg-20160331.xml Edgar Link completed
bstg-20160331.xsd Edgar Link pending
bstg-20160331_cal.xml Edgar Link unprocessable
bstg-20160331_def.xml Edgar Link unprocessable
bstg-20160331_lab.xml Edgar Link unprocessable
bstg-20160331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v439267_10q.htm Edgar Link pending
v439267_ex31-1.htm Edgar Link pending
v439267_ex31-2.htm Edgar Link pending
v439267_ex32-1.htm Edgar Link pending
v439267_ex32-2.htm Edgar Link pending